HCV Drug Discovery
Hilton San Diego Resort

San Diego, California


   It is an exciting time for the field of HCV antivirals. Viral protease
   and polymerase inhibitors are in late stage clinical trials, as are
   combinations of them, suggesting an interferon-free drug cocktail to
   treat HCV may one day be possible. Progress is also being made on
   small molecule drug candidates that inhibit host proteins involved in
   the maturation/processing of HCV particles.

Schedule of Presentations:

Wednesday, April 28, 2010
12:30:00 Registration
13:25:00 Inhibiting HCV Polymerase (NS5B)
13:30:00 Chairperson's Opening Remarks
13:40:00 Structure-Based Design of Non-Nucleoside NS5B Inhibitors for the Treatment of HCV Francisco Talamas
14:10:00 PSI-7851: Development of a Nucleotide Prodrug for the Treatment of HCV Michael J. Sofia
14:40:00 Novel Phosphoramidate HCV NS5b Inhibitors Joseph M Patti
15:10:00 Sponsored Presentations (Opportunity Available)
15:40:00 Networking Refreshment Break, Poster and Exhibit Viewing
16:15:00 Inhibiting HCV NS5A
16:20:00 The Identification and Optimization of HCV Replicon Inhibitors Characterised by NS5A Specific Mutations Stuart Cockerill
16:50:00 Discovery and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Broad-Spectrum Coverage of all HCV Genotypes Richard Colonno
17:20:00 Break-Out Discussions
18:30:00 End of Day
Thursday, April 29, 2010
07:30:00 Breakfast Workshop Presentation (Sponsorship Opportunity Available) or Morning Coffee
08:10:00 Inhibiting HCV Protease
08:15:00 Chairperson's Opening Remarks
08:20:00 KEYNOTE Telaprevir: Discovery, Homologues and Clinical Update Youssef Bennani
09:00:00 Protein Silencing of Hepatitis C Virus NS3/4A Protease in vitro and in vivo With AVL-181 Juswinder Singh
09:30:00 Recent Developments in HCV NS3/4A Protease Inhibitor Nigel Liverton
10:00:00 Networking Coffee Break, Poster and Exhibit Viewing
10:45:00 Boron and Non-Boron-Based HCV NS3/4 Protease InIhibitors: Discovery of a Novel Motif Possessing High Potency against PI-Resistant Mutants Wieslaw Kazmierski
11:15:00 HCV-Protease Inhibitors: Current and the Next Generation Atul Agarwal
11:45:00 TMC435 Clinical Update and In Vitro Combination Kenny Simmen
12:15:00 Sponsored Presentation (Opportunity Available)
12:30:00 Walk and Talk Luncheon in the Exhibit Hall (Last Chance for Poster and Exhibit Viewing)
13:50:00 New Viral Targets
13:55:00 Chairperson's Remarks
14:00:00 Discovery of Potent and Mechanistically Distinct Inhibitors of HCV Entry William C. Olson
14:30:00 Core Protein: A New Target for the Development of Novel Small Molecule Inhibitors of HCV A. Donny Strosberg
15:00:00 Networking Refreshment Break
15:15:00 Targeting The Host
15:20:00 Development of SR-B1 Modulators as HCV Entry Inhibitors Jeffrey McKelvy
15:50:00 Targeting TLR7 James Appleman
16:20:00 Mechanism of HCV Resistance to Cyclophilin Inhibitors Hengli Tang
16:50:00 End of Conference
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.